Diligence memo · auto-generated · as of July 2, 2026
Siren Biotechnology, Inc.
Siren Biotechnology, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Siren Biotechnology, Inc. operates in Biotech, based in SAN FRANCISCO.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Siren Biotechnology, Inc. has raised $20M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2024-04-08.
Most recent recorded round closed around 2024-04-08.
Valuation (modeled)modeled
Provath models Siren Biotechnology, Inc. at approximately $154M (range $39M–$289M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series B Biotech companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.2 yr ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 89% of Biotech peers (233 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Watchmaker Genomics, Inc., Mytos, Inc., ZBiotics Co, Invert, Inc., AgNovos Bioscience, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.